Thera-SAbDab

TRINBELIMAB

>   Structural Summary
TherapeuticTrinbelimab
TargetRhD
Heavy ChainQVQLVQSGAEVKKPGSSVKVSCKASGGIFRTYAISWVRQAPGQGLEWMGGIIPMFGTVNYAQKFQGRVTISADKSTSTAYMELSRLRSEDTAVYYCARPPSGGCGGDCSRYGYYYAMDVWGQGTTITVSS
Light ChainQSALTQPASVSGSPGQSITISCSGSSSDVGGYKYVSWYQQHPGKAPQLMIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGGGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)TBC
Estimated Status (October '21)Active
Recorded Developmental Technologyna
INN Year Proposed2021
INN Year RecommendedNone
Companies InvolvedBharat Serums and Vaccines
Conditions ApprovedTBC
Conditions ActiveTBC
Conditions DiscontinuedTBC
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy